We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Increased Risk of Hypoandrogenemia Found in Obese Young Men

By LabMedica International staff writers
Posted on 12 Sep 2019
Hyperandrogenism is a medical condition characterized by high levels of androgens in females, but men with obesity may be at increased risk for developing hypoandrogenemia or low free testosterone, especially if they have more severe obesity.

A laboratory test can also be done on the patient to evaluate levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), dehydroepiandrosterone sulfate (DHEAS), prolactin, 17α-Hydroxyprogesterone (17OHP), and total and free testosterone in the patient's blood. More...
Abnormally high levels of any of these hormones help in diagnosing hyperandrogenism.

Endocrinologists at the Virgen de la Victoria University Hospital (Malaga, Spain) and their colleagues conducted a cross-sectional study with 266 men with obesity that were younger than 50 years and did not have diabetes (mean age, 36.9 years; mean BMI, 39 kg/m2). Participants were recruited from primary care offices in Malaga, Spain, between June 2013 and June 2015.

The scientists measured total testosterone by high‐performance liquid chromatography mass spectrometry, sex hormone–binding globulin, free testosterone (FT), LH, high‐sensitivity C‐reactive protein, and homeostatic model assessment of insulin resistance were also determined. Body composition and erectile function were also assessed. Hypoandrogenemia was defined as FT level < 70 pg/mL.

The team reported that fasting testosterone levels of less than 70 pg/mL were found in 25.6% of the participants, which they used as the threshold for hypoandrogenemia. Participants with a BMI of more than 50 kg/m2 had a particularly high prevalence of hypoandrogenemia (78.3%), whereas those with a BMI of 40 kg/m2 to 49.9 kg/m2 (33.8%), 35 kg/m2 to 39.9 kg/m2 (19.8%) and 30 kg/m2 to 34.9 kg/m2 (11.1%) had a lower prevalence.

The team noted that the associations between fasting testosterone and BMI, waist circumference, fat mass percentage, visceral fat, HbA1c, high-sensitivity C-reactive protein, insulin and insulin resistance were all negative whereas the associations between fasting testosterone and luteinizing hormone and fat-free mass percentage were positive. In terms of hypoandrogenemia-identifying free testosterone levels, they stated that there was an association with waist circumference, fat mass percentage, high-sensitivity C-reactive protein, BMI, diastolic blood pressure and HbA1c. They also stated that “protective factors” for the condition included elevated fat-free mass percentage and elevated luteinizing hormone levels.

José C. Fernández-García, MD, PhD, an Associate Professor and a senior author of the study, said, “The finding of a subnormal level of testosterone is not a trivial issue. Although often overlooked and underdiagnosed, hypoandrogenemia is associated with visceral obesity, reduced lean body mass, type 2 diabetes, the metabolic syndrome, sexual dysfunction, impaired erectile function and decreased quality of life.” The study was published on August 14, 2019, in the journal Obesity.

Related Links:
Virgen de la Victoria University Hospital


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Urine Analyzer
respons® UDS100
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.